Navigation

Gene expression profiling and expanded immunohistochemistry tests to guide the use of adjuvant chemotherapy in early breast cancer management: MammaPrint, Oncotype DX, IHC4 and Mammostrat

Gene expression profiling and expanded immunohistochemistry tests to guide the use of adjuvant chemotherapy in early breast cancer management: MammaPrint, Oncotype DX, IHC4 and Mammostrat

Status: History
Publication Date: September 2013
Topic area:
  • Cancer
  • Diagnostic procedures
 

NICE project team

Patient involvement Lead: Laura Norburn
Lead analyst: Gurleen Jhuti
Communications manager: Phil Ranson
Project manager: Robert Fernley
Implementation Lead: Katie Perryman-Ford
Top


 

Provisional schedule

Scoping workshop: 2 March 2011
1st committee meeting: 04 January 2012
2nd committee meeting 09 January 2013
Top


 

Stakeholders

Notifying manufacturer

  • Randox Laboratories Limited

Manufacturer(s) of alternative technologies

  • Genomic Health
  • GE Healthcare
  • Roche Diagnostics
  • Clarient 

Professional groups

  • Royal College of Physicians
  • The Royal College of Pathologists

Patient/carer groups

  • Breakthrough Breast Cancer

External Assessment Group

  • School of Health and Related Research (ScHARR)

Others

  • Agendia Bvd
  • Department of Health
  • Health Improvement Scotland
  • ARUP Laboratories
  • AstraZeneca
  • UCL Hospitals, London
  • Nottingham Prognostics
  • Ipsogen Inc
  • The Royal Marsden NHS Trust
  • Southport & Ormskirk Hospital NHS Trust

Definition: Registered stakeholders

Individuals or organisations interested in a topic being evaluated by the Diagnostics Assessment Programme, and who register to become a stakeholder. For example, manufacturers of the technology, national organisations that represent healthcare professions who operate or use the results of the technology, national patient or carer organisations, NHS service providers and commissioners, statutory organisations and research organisations.

Top


 

Project history

Date Update
25 September 2013 Guideline publishes
10 April 2013 3rd committee meeting
Top


 

Key documents

This page was last updated: 20 September 2013

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.